世界のネオアンチゲン癌ワクチン市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neoantigen Cancer Vaccine Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4561
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、107ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、ネオアンチゲン癌ワクチンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（個人特定ワクチン、既製ネオワクチン）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・ネオアンチゲン癌ワクチンの市場動向
・企業の競争状況、市場シェア
・ネオアンチゲン癌ワクチンの種類別市場規模と予測2016-2027（個人特定ワクチン、既製ネオワクチン）
・ネオアンチゲン癌ワクチンの用途別市場規模と予測2016-2027（病院、クリニック、その他）
・ネオアンチゲン癌ワクチンの北米市場規模2016-2027（アメリカ、カナダ）
・ネオアンチゲン癌ワクチンの欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・ネオアンチゲン癌ワクチンのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ネオアンチゲン癌ワクチンの中南米市場規模2016-2027（メキシコ、ブラジル）
・ネオアンチゲン癌ワクチンの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Roche、Medimmune、Merck、Advaxis、Agenus、Genocea、Gritstone Oncology、Neon Therapeutics、Nouscom、OSE Immunotherapeutics、Medigene、Vaccibody、Brightpath Biotherapeutics、Geneos Therapeutics）
・結論

It is through the use of tumor cell-associated antigens to awaken the body’s immune system against cancer.

Market Analysis and Insights: Global Neoantigen Cancer Vaccine Market
The global Neoantigen Cancer Vaccine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neoantigen Cancer Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neoantigen Cancer Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neoantigen Cancer Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neoantigen Cancer Vaccine market.

Global Neoantigen Cancer Vaccine Scope and Market Size
Neoantigen Cancer Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neoantigen Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Personalized Vaccine
Off-the-shelf Neovaccines

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Roche
Medimmune
Merck
Advaxis
Agenus
Genocea
Gritstone Oncology
Neon Therapeutics
Nouscom
OSE Immunotherapeutics
Medigene
Vaccibody
Brightpath Biotherapeutics
Geneos Therapeutics

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neoantigen Cancer Vaccine Market Perspective (2016-2027)
2.2 Neoantigen Cancer Vaccine Growth Trends by Regions
2.2.1 Neoantigen Cancer Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neoantigen Cancer Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Neoantigen Cancer Vaccine Industry Dynamic
2.3.1 Neoantigen Cancer Vaccine Market Trends
2.3.2 Neoantigen Cancer Vaccine Market Drivers
2.3.3 Neoantigen Cancer Vaccine Market Challenges
2.3.4 Neoantigen Cancer Vaccine Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2016-2021)
3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2020
3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2022-2027)

5 Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neoantigen Cancer Vaccine Market Size (2016-2027)
6.2 North America Neoantigen Cancer Vaccine Market Size by Type
6.2.1 North America Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
6.2.2 North America Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
6.2.3 North America Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
6.3 North America Neoantigen Cancer Vaccine Market Size by Application
6.3.1 North America Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
6.3.2 North America Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
6.3.3 North America Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
6.4 North America Neoantigen Cancer Vaccine Market Size by Country
6.4.1 North America Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
6.4.2 North America Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neoantigen Cancer Vaccine Market Size (2016-2027)
7.2 Europe Neoantigen Cancer Vaccine Market Size by Type
7.2.1 Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
7.3 Europe Neoantigen Cancer Vaccine Market Size by Application
7.3.1 Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
7.4 Europe Neoantigen Cancer Vaccine Market Size by Country
7.4.1 Europe Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type
8.2.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application
8.3.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region
8.4.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Market Size (2016-2027)
9.2 Latin America Neoantigen Cancer Vaccine Market Size by Type
9.2.1 Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
9.3 Latin America Neoantigen Cancer Vaccine Market Size by Application
9.3.1 Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
9.4 Latin America Neoantigen Cancer Vaccine Market Size by Country
9.4.1 Latin America Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type
10.2.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application
10.3.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country
10.4.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Introduction
11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Medimmune
11.2.1 Medimmune Company Details
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.2.5 Medimmune Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Introduction
11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Advaxis
11.4.1 Advaxis Company Details
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.4.5 Advaxis Recent Development
11.5 Agenus
11.5.1 Agenus Company Details
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.5.5 Agenus Recent Development
11.6 Genocea
11.6.1 Genocea Company Details
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.6.5 Genocea Recent Development
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Details
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.7.5 Gritstone Oncology Recent Development
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Details
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.8.5 Neon Therapeutics Recent Development
11.9 Nouscom
11.9.1 Nouscom Company Details
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.9.5 Nouscom Recent Development
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Details
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.10.5 OSE Immunotherapeutics Recent Development
11.11 Medigene
11.11.1 Medigene Company Details
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.11.5 Medigene Recent Development
11.12 Vaccibody
11.12.1 Vaccibody Company Details
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.12.5 Vaccibody Recent Development
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Details
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.13.5 Brightpath Biotherapeutics Recent Development
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Details
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.14.5 Geneos Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the-shelf Neovaccines
Table 4. Global Neoantigen Cancer Vaccine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Neoantigen Cancer Vaccine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neoantigen Cancer Vaccine Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Neoantigen Cancer Vaccine Market Share by Regions (2016-2021)
Table 8. Global Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Neoantigen Cancer Vaccine Market Share by Regions (2022-2027)
Table 10. Neoantigen Cancer Vaccine Market Trends
Table 11. Neoantigen Cancer Vaccine Market Drivers
Table 12. Neoantigen Cancer Vaccine Market Challenges
Table 13. Neoantigen Cancer Vaccine Market Restraints
Table 14. Global Neoantigen Cancer Vaccine Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Neoantigen Cancer Vaccine Market Share by Players (2016-2021)
Table 16. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neoantigen Cancer Vaccine as of 2020)
Table 17. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neoantigen Cancer Vaccine Product Solution and Service
Table 21. Date of Enter into Neoantigen Cancer Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2016-2021)
Table 25. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Neoantigen Cancer Vaccine Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2016-2021)
Table 29. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Neoantigen Cancer Vaccine Product
Table 64. Roche Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Medimmune Company Details
Table 67. Medimmune Business Overview
Table 68. Medimmune Neoantigen Cancer Vaccine Product
Table 69. Medimmune Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 70. Medimmune Recent Development
Table 71. Merck Company Details
Table 72. Merck Business Overview
Table 73. Merck Neoantigen Cancer Vaccine Product
Table 74. Merck Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 75. Merck Recent Development
Table 76. Advaxis Company Details
Table 77. Advaxis Business Overview
Table 78. Advaxis Neoantigen Cancer Vaccine Product
Table 79. Advaxis Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 80. Advaxis Recent Development
Table 81. Agenus Company Details
Table 82. Agenus Business Overview
Table 83. Agenus Neoantigen Cancer Vaccine Product
Table 84. Agenus Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 85. Agenus Recent Development
Table 86. Genocea Company Details
Table 87. Genocea Business Overview
Table 88. Genocea Neoantigen Cancer Vaccine Product
Table 89. Genocea Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 90. Genocea Recent Development
Table 91. Gritstone Oncology Company Details
Table 92. Gritstone Oncology Business Overview
Table 93. Gritstone Oncology Neoantigen Cancer Vaccine Product
Table 94. Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 95. Gritstone Oncology Recent Development
Table 96. Neon Therapeutics Company Details
Table 97. Neon Therapeutics Business Overview
Table 98. Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 99. Neon Therapeutics Recent Development
Table 100. Nouscom Company Details
Table 101. Nouscom Business Overview
Table 102. Nouscom Neoantigen Cancer Vaccine Product
Table 103. Nouscom Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 104. Nouscom Recent Development
Table 105. OSE Immunotherapeutics Company Details
Table 106. OSE Immunotherapeutics Business Overview
Table 107. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product
Table 108. OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 109. OSE Immunotherapeutics Recent Development
Table 110. Medigene Company Details
Table 111. Medigene Business Overview
Table 112. Medigene Neoantigen Cancer Vaccine Product
Table 113. Medigene Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 114. Medigene Recent Development
Table 115. Vaccibody Company Details
Table 116. Vaccibody Business Overview
Table 117. Vaccibody Neoantigen Cancer Vaccine Product
Table 118. Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 119. Vaccibody Recent Development
Table 120. Brightpath Biotherapeutics Company Details
Table 121. Brightpath Biotherapeutics Business Overview
Table 122. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product
Table 123. Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 124. Brightpath Biotherapeutics Recent Development
Table 125. Geneos Therapeutics Company Details
Table 126. Geneos Therapeutics Business Overview
Table 127. Geneos Therapeutics Neoantigen Cancer Vaccine Product
Table 128. Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 129. Geneos Therapeutics Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Cancer Vaccine Market Share by Type: 2020 VS 2027
Figure 2. Personalized Vaccine Features
Figure 3. Off-the-shelf Neovaccines Features
Figure 4. Global Neoantigen Cancer Vaccine Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Neoantigen Cancer Vaccine Report Years Considered
Figure 9. Global Neoantigen Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Neoantigen Cancer Vaccine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Neoantigen Cancer Vaccine Market Share by Regions: 2020 VS 2027
Figure 12. Global Neoantigen Cancer Vaccine Market Share by Regions (2022-2027)
Figure 13. Global Neoantigen Cancer Vaccine Market Share by Players in 2020
Figure 14. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neoantigen Cancer Vaccine as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2020
Figure 16. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2016-2021)
Figure 17. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2022-2027)
Figure 18. North America Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 20. North America Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 21. North America Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 22. United States Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 26. Europe Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 27. Europe Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 28. Germany Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Region (2016-2027)
Figure 38. China Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 46. Latin America Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 47. Latin America Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 48. Mexico Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 54. Turkey Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 58. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 59. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 60. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 61. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 62. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 63. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 64. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 65. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 66. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 67. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 68. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 69. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 70. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

以下、関連資料のご紹介

世界のネオアンチゲン標的療法市場規模・現状・予測（2021年-2027年）

Global Neoantigen Targeted Therapies Market Size, Status and Forecast 2021-2027
QFJ1-5264 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、ネオアンチゲン標的療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（単剤療法、併用療法）、用途別市場規模（医療研究機関、病院・クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、...

世界の樹状細胞癌ワクチン免疫療法市場規模・現状・予測（2021年-2027年）

Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, Status and Forecast 2021-2027
QFJ1-5694 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、樹状細胞癌ワクチン免疫療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（プロベンジ、アプセデン、CreaVax、その他）、用途別市場規模（小児科、成人用）、主要地域別市場規模（北米、アメリカ、欧州、...

世界のmRNAワクチン＆治療薬市場規模・現状・予測（2021年-2027年）

Global mRNA Vaccine And Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4530 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、mRNAワクチン＆治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（感染症、がん、その他）、用途別市場規模（病院、研究所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イン...

世界の水産養殖用ワクチン市場規模・現状・予測（2021年-2027年）

Global Aquaculture Vaccine Market Size, Status and Forecast 2021-2027
QFJ1-5596 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、水産養殖用ワクチンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（生ワクチン、不活化ワクチン、その他ワクチン）、用途別市場規模（ウイルス感染、細菌感染、その他）、主要地域別市場規模（北米、アメリカ、欧...

世界の髄膜炎菌感染症ワクチン市場規模・現状・予測（2021年-2027年）

Global Meningococcal Infections Vaccine Market Size, Status and Forecast 2021-2027
QFJ1-4491 2021年6月 85Pages
QYResearch社発行の本調査レポートでは、髄膜炎菌感染症ワクチンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（4価（血清型A＆C＆W-135＆Y）、2価（血清型C＆Y）、血清型A、血清型B、血清型X）、用途別市場規模（病院、クリニック）、主...

世界のハラールワクチン市場規模・現状・予測（2021年-2027年）

Global Halal Vaccine Market Size, Status and Forecast 2021-2027
QFJ1-5765 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、ハラールワクチンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（はしか-風疹ワクチン、髄膜炎菌性髄膜炎ワクチン、その他）、用途別市場規模（政府機関、病院、NGO）、主要地域別市場規模（北米、アメリカ、...

世界のワクチン受託製造市場規模・現状・予測（2021年-2027年）

Global Vaccine Contract Manufacturing Market Size, Status and Forecast 2021-2027
QFJ1-5010 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ワクチン受託製造の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（充填仕上げ、バルク製品）、用途別市場規模（製薬企業、バイオ企業、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、...

世界の点鼻ワクチン市場規模・現状・予測（2021年-2027年）

Global Nasal Spray Vaccine Market Size, Status and Forecast 2021-2027
QFJ1-4550 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、点鼻ワクチンの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（インフルエンザワクチン、新型コロナウイルス感染症ワクチン、その他ワクチン）、用途別市場規模（大人用、子供用）、主要地域別市場規模（北米、アメ...

世界の肺炎球菌コンジュゲートワクチン（PCV）市場規模・現状・予測（2021年-2027年）

Global Pneumococcal Conjugate Vaccine (PCV) Market Size, Status and Forecast 2021-2027
QFJ1-5956 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、肺炎球菌コンジュゲートワクチン（PCV）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（23価ワクチン、10価ワクチン、7価ワクチン、13価ワクチン）、用途別市場規模（子供用、大人用）、主要地域別市場...

世界の子宮頸がん治療薬市場規模・現状・予測（2021年-2027年）

Global Cervical Cancer Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-5652 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、子宮頸がん治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品、ワクチン）、用途別市場規模（病院薬局、ドラッグストア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イン...

世界の樹状細胞癌ワクチン免疫療法市場規模・現状・予測（2021年-2027年） Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These …
世界のネオアンチゲン標的療法市場規模・現状・予測（2021年-2027年） Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Cancer neoantigens is a term used to refer to a subset of antigens encoded by tumor-specific, mutated genes, which have n…
子宮頸がんワクチンのグローバル市場調査 2019年 The global Cervical Cancer Vaccine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Cervical Cancer Vaccine volume and value at global level, regional level and company level. From a global perspecti…
ペプチドがんワクチンのグローバル市場2021 Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitu…
世界の髄膜炎菌感染症ワクチン市場規模・現状・予測（2021年-2027年） Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis.Different versions are effective against some or all of the following types of meningococcus: A, C, W-135,and Y.The vaccines are between 85 and 100% effective for at least two years.They result in…